Due to its enhanced anabolic effect on bone formation and its diminished catabolic effect on bone resorption, sclerostin antibody therapy has been proposed as a new treatment for postmenopausal osteoporosis [41, 42]. The gene discussed is SOST; the disease is postmenopausal osteoporosis.